Antonio Medina de Almeida
AuthID: R-000-T91
41
TITLE: EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) Full Text
AUTHORS: Garcia Manero, G; Santini, V; Almeida, A; Fenaux, P; Gattermann, N; Ozawa, K; Goldberg, SL; Weaver, J; Sugrue, MM;
PUBLISHED: 2017, SOURCE: 14th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 55
AUTHORS: Garcia Manero, G; Santini, V; Almeida, A; Fenaux, P; Gattermann, N; Ozawa, K; Goldberg, SL; Weaver, J; Sugrue, MM;
PUBLISHED: 2017, SOURCE: 14th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 55
INDEXED IN: 
WOS
WOS IN MY: 
ORCID
ORCID42
TITLE: IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) Full Text
AUTHORS: Santini, V; Fenaux, P; Giagounidis, A; Platzbecker, U; Almeida, A; List, AF; Zhong, J; Wu, C; Mavrommatis, K; Beach, CL; MacBeth, KJ;
PUBLISHED: 2017, SOURCE: 14th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 55
AUTHORS: Santini, V; Fenaux, P; Giagounidis, A; Platzbecker, U; Almeida, A; List, AF; Zhong, J; Wu, C; Mavrommatis, K; Beach, CL; MacBeth, KJ;
PUBLISHED: 2017, SOURCE: 14th International Symposium on Myelodysplastic Syndromes (MDS) in LEUKEMIA RESEARCH, VOLUME: 55
43
TITLE: IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) Full Text
AUTHORS: Santini, V; Fenaux, P; Giagounidis, A; Platzbecker, U; Almeida, A; List, AF; Zhong, J; Wu, C; Mavrommatis, K; Beach, CL; MacBeth, KJ;
PUBLISHED: 2017, SOURCE: 46th Congress of the Italian-Society-of-Hematology in HAEMATOLOGICA, VOLUME: 102
AUTHORS: Santini, V; Fenaux, P; Giagounidis, A; Platzbecker, U; Almeida, A; List, AF; Zhong, J; Wu, C; Mavrommatis, K; Beach, CL; MacBeth, KJ;
PUBLISHED: 2017, SOURCE: 46th Congress of the Italian-Society-of-Hematology in HAEMATOLOGICA, VOLUME: 102
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID44
TITLE: CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS Full Text
AUTHORS: Pfirrmann, M; Mahon, FX; Guilhot, J; Richter, J; Almeida, A; Janssen, JJ; Mayer, J; Koskenvesa, P; Panayiotidis, P; Olsson Stromberg, U; Berger, MG; Diamond, J; Ehrencrona, H; Kairisto, V; Polakova, KM; Mueller, MC; Mustjoki, S; Hochhaus, A; Saussele, S; Hjorth Hansen, H;
PUBLISHED: 2017, SOURCE: HAEMATOLOGICA, VOLUME: 102
AUTHORS: Pfirrmann, M; Mahon, FX; Guilhot, J; Richter, J; Almeida, A; Janssen, JJ; Mayer, J; Koskenvesa, P; Panayiotidis, P; Olsson Stromberg, U; Berger, MG; Diamond, J; Ehrencrona, H; Kairisto, V; Polakova, KM; Mueller, MC; Mustjoki, S; Hochhaus, A; Saussele, S; Hjorth Hansen, H;
PUBLISHED: 2017, SOURCE: HAEMATOLOGICA, VOLUME: 102
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID45
TITLE: Effect of Lenalidomide Exposure on Response and Outcomes in Patients with Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes (MDS) Full Text
AUTHORS: Garcia-Manero, G; Santini, V; Almeida, A; Fenaux, P; Gattermann, N; Ozawa, K; S.L Goldberg; Weaver, J; M.M Sugrue;
PUBLISHED: 2017, SOURCE: Leukemia Research, VOLUME: 55
AUTHORS: Garcia-Manero, G; Santini, V; Almeida, A; Fenaux, P; Gattermann, N; Ozawa, K; S.L Goldberg; Weaver, J; M.M Sugrue;
PUBLISHED: 2017, SOURCE: Leukemia Research, VOLUME: 55
46
TITLE: STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL Full Text
AUTHORS: Richter, J; Mahon, FX; Guilhot, J; Hjorth Hansen, H; Almeida, A; Janssen, JJ; Mayer, J; Porkka, K; Panayiotidis, P; Olsson Stromberg, U; Berger, MG; Diamond, J; Ehrencrona, H; Kairisto, V; Machova M Polakova; Muller, MC; Mustjoki, S; Hochhaus, A; Pfirrmann, M; Saussele, S;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
AUTHORS: Richter, J; Mahon, FX; Guilhot, J; Hjorth Hansen, H; Almeida, A; Janssen, JJ; Mayer, J; Porkka, K; Panayiotidis, P; Olsson Stromberg, U; Berger, MG; Diamond, J; Ehrencrona, H; Kairisto, V; Machova M Polakova; Muller, MC; Mustjoki, S; Hochhaus, A; Pfirrmann, M; Saussele, S;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID47
TITLE: CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q) Full Text
AUTHORS: Garcia Manero, G; Almeida, A; Fenaux, P; Gattermann, N; Giagounidis, A; Goldberg, S; Ozawa, K; Weaver, J; Sugrue, MM; Santini, V;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
AUTHORS: Garcia Manero, G; Almeida, A; Fenaux, P; Gattermann, N; Giagounidis, A; Goldberg, S; Ozawa, K; Weaver, J; Sugrue, MM; Santini, V;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID48
TITLE: TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS Full Text
AUTHORS: Almeida, A; Fenaux, P; Garcia Manero, G; Giagounidis, A; Goldberg, S; Groepper, S; Jonasova, A; Mufti, GJ; Sanz, GF; Vey, N; Castaneda, C; Zhong, J; Beach, C; Santini, V;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
AUTHORS: Almeida, A; Fenaux, P; Garcia Manero, G; Giagounidis, A; Goldberg, S; Groepper, S; Jonasova, A; Mufti, GJ; Sanz, GF; Vey, N; Castaneda, C; Zhong, J; Beach, C; Santini, V;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID49
TITLE: MTOR INHIBITION IN CML: A NEW THERAPEUTIC OPTION Full Text
AUTHORS: Alves, RS; Ana Cristina Gonçalves ; Couceiro, P; Paulo Rodrigues-Santos ; Freitas-Tavares, Paulo; Ribeiro, L; Almeida, A; Sarmento Ribeiro, AB;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
AUTHORS: Alves, RS; Ana Cristina Gonçalves ; Couceiro, P; Paulo Rodrigues-Santos ; Freitas-Tavares, Paulo; Ribeiro, L; Almeida, A; Sarmento Ribeiro, AB;
PUBLISHED: 2016, SOURCE: 21st Congress of the European-Hematology-Association in HAEMATOLOGICA, VOLUME: 101
INDEXED IN: WOS
WOS IN MY: ORCID
ORCID50
TITLE: REAL -WORLD EVIDENCE OF RUXOLITINIB IN THE TREATMENT OF MYELOFIBROSIS: EXPERINCE OF A PORTUGUESE HOSPITAL CENTER Full Text
AUTHORS: Almeida, A; Alnajjar, K; Viriato, D;
PUBLISHED: 2016, SOURCE: VALUE IN HEALTH, VOLUME: 19, ISSUE: 7
AUTHORS: Almeida, A; Alnajjar, K; Viriato, D;
PUBLISHED: 2016, SOURCE: VALUE IN HEALTH, VOLUME: 19, ISSUE: 7
